Nubeqa Tablet contains Darolutamide 300 mg, a nonsteroidal androgen receptor inhibitor indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). Darolutamide works by selectively binding to androgen receptors, thereby inhibiting the action of androgens which play a critical role in the progression of prostate cancer. This mechanism helps to delay the development of metastases and prolong overall survival in affected patients. Nubeqa is administered orally, typically at a dose of 300 mg twice daily, and is used in combination with androgen deprivation therapy (ADT). Clinical studies have demonstrated its efficacy in reducing the risk of metastasis or death compared to placebo, with a favorable safety profile characterized by low incidence of central nervous system-related adverse effects due to its limited blood-brain barrier penetration. Common side effects may include fatigue, pain, rash, and hypertension, although most are mild to moderate in severity. Nubeqa should be prescribed and monitored by healthcare professionals experienced in oncology, with attention to potential drug interactions and patient comorbidities. It is contraindicated in patients with hypersensitivity to Darolutamide or any of its excipients. Regular follow-up is essential to assess therapeutic response and manage any adverse events.